223 related articles for article (PubMed ID: 31820498)
21. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
23. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.
Griffiths CE; Sterry W; Brock F; Dilleen M; Stefanidis D; Germain JM; Mallbris L
Br J Dermatol; 2015 Jan; 172(1):230-8. PubMed ID: 24861696
[TBL] [Abstract][Full Text] [Related]
24. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
25. Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.
Bourcier M; Papp KA; Gulliver WP; Poulin Y; Barber K; Poulin-Costello M; Shelton J
J Cutan Med Surg; 2015; 19(6):561-9. PubMed ID: 25951825
[TBL] [Abstract][Full Text] [Related]
26. Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients.
E C; Fang Y; Wu S; Meng Z; Qin G; Yang J
J Clin Lab Anal; 2022 Feb; 36(2):e24199. PubMed ID: 34973040
[TBL] [Abstract][Full Text] [Related]
27. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
[TBL] [Abstract][Full Text] [Related]
28. The potential of circulating microRNA-125a and microRNA-125b as markers for inflammation and clinical response to infliximab in rheumatoid arthritis patients.
Cheng P; Wang J
J Clin Lab Anal; 2020 Aug; 34(8):e23329. PubMed ID: 32281166
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.
Fonseca E; Iglesias R; Paradela S; Fernández-Torres RM; Elberdín L
J Dermatolog Treat; 2015 Jun; 26(3):217-22. PubMed ID: 24920071
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
31. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
[TBL] [Abstract][Full Text] [Related]
32. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
[TBL] [Abstract][Full Text] [Related]
34. Elevated circulating lnc-ANRIL/miR-125a axis level predicts higher risk, more severe disease condition, and worse prognosis of sepsis.
Gui F; Peng H; Liu Y
J Clin Lab Anal; 2019 Jul; 33(6):e22917. PubMed ID: 31115097
[TBL] [Abstract][Full Text] [Related]
35. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-125a Correlates with Decreased Psoriasis Severity and Inflammation and Represses Keratinocyte Proliferation.
Su F; Jin L; Liu W
Dermatology; 2021; 237(4):568-578. PubMed ID: 33735868
[TBL] [Abstract][Full Text] [Related]
37. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
[TBL] [Abstract][Full Text] [Related]
38. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-125a-5p regulates the effect of Tregs on Th1 and Th17 through targeting ETS-1/STAT3 in psoriasis.
Yan K; Zhang F; Ren J; Huang Q; Yawalkar N; Han L
J Transl Med; 2023 Sep; 21(1):678. PubMed ID: 37773129
[TBL] [Abstract][Full Text] [Related]
40. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-α therapy.
Pivarcsi A; Meisgen F; Xu N; Ståhle M; Sonkoly E
Br J Dermatol; 2013 Sep; 169(3):563-70. PubMed ID: 23600954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
